#VisualAbstract: Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Tag: enzalutamide
Talazoparib plus enzalutamide improves progression-free survival in metastatic prostate cancer
1. Progression-free survival was significantly higher in the talazoparib plus enzalutamide group compared to enzalutamide alone. 2. There were no ...
#VisualAbstract: Continued enzalutamide after progression of metastatic prostate cancer improves progression-free survival
1. The median progression-free survival was higher in the enzalutamide vs the placebo group (9.5 months vs 8.3 months) 2. ...
Continued enzalutamide after progression of metastatic prostate cancer improves progression-free survival
1. The median progression-free survival was higher in the enzalutamide vs the placebo group (9.5 months vs 8.3 months). 2. ...
#VisualAbstract: Abiraterone acetate improves survival in high-risk non-metastatic prostate cancer compared to control
1. Abiraterone acetate plus standard treatment significantly increased length of metastasis-free survival in men with non-metastatic prostate cancer compared to ...
#VisualAbstract: Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
1. Enzalutamide along with androgen-deprivation therapy was shown to significantly increase median overall survival among men with non-metastatic, castration-resistant prostate ...
Enzalutamide treatment increases median overall survival in non-metastatic prostate cancer
1. Enzalutamide along with androgen-deprivation therapy was shown to significantly increase median overall survival among men with non-metastatic, castration-resistant prostate ...
Enzalutamide reduces risk of metastatic prostate cancer in at-risk men
1. Prostate cancer patients with a rapidly risking prostate-specific antigen (PSA) despite chemical or physical castration had lower rates of ...